Fundraising Fox
Raj Parekh
InvestorGeneral Partner at Advent Life Sciences · Strategic Advisor at Silicon Catalyst
Los Altos, California
Writes $25K – $5M checks · typically $1M
Find your path to Raj
Sign up to see every warm intro you have to Raj
- Paths you didn't know you had: your email and LinkedIn already hold routes to Raj. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Raj Parekh joined Advent in 2005, bringing over 20 years of experience across biomedical research, entrepreneurship, and investing. He holds an MA and DPhil from Oxford University, worked in molecular medicine academia, and co-founded Oxford GlycoSciences (which went public on the LSE and NASDAQ and was later sold to UCB-Celltech). He has also served as Chairman of Galapagos nv, on the Supervisory Board of the Novartis Venture Fund, and as a founding Director of Celldex Therapeutics. At Advent, he focuses on founding and supporting portfolio companies developing new medicines.
Contact· self-published, not guessed
Invests in
Biotech
Deals · 3
Artax BiopharmaBoard seat
via Advent Life Sciences · filed May 2026 · $19M raise
Macrolide PharmaceuticalsBoard seat
via Advent Life Sciences · filed Mar 2018 · $20M raise
Arrakis TherapeuticsBoard seat
via Advent Life Sciences · filed Mar 2017 · $41.2M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
ALETAAmphista TherapeuticsArtaxAura BiosciencesAvila TherapeuticsCn CreativeEUSA PharmaLevicept
Investor
Amphista TherapeuticsAvila TherapeuticsBiocartis Group NVF2GLeviceptNerre TherapeuticsRappta TherapeuticsThiakisZikani Therapeutics
Sources: the firm's website · SEC Form D filings · curated public sources.
Colleagues at Advent Life Sciences
Frequently asked questions
- Who is Raj Parekh?
- Raj Parekh joined Advent in 2005, bringing over 20 years of experience across biomedical research, entrepreneurship, and investing. He holds an MA and DPhil from Oxford University, worked in molecular medicine academia, and co-founded Oxford GlycoSciences (which went public on the LSE and NASDAQ and was later sold to UCB-Celltech). He has also served as Chairman of Galapagos nv, on the Supervisory Board of the Novartis Venture Fund, and as a founding Director of Celldex Therapeutics. At Advent, he focuses on founding and supporting portfolio companies developing new medicines.
- Where does Raj Parekh work?
- Raj Parekh is General Partner at Advent Life Sciences and Strategic Advisor at Silicon Catalyst.
- What does Raj Parekh invest in?
- Raj Parekh invests in Biotech.
- What check size does Raj Parekh write?
- Raj Parekh typically writes checks of $25K – $5M.
- What boards does Raj Parekh sit on?
- Raj Parekh holds tracked board seats at ALETA, Amphista Therapeutics, Arrakis Therapeutics, Arrakis Therapeutics, Artax, Artax Biopharma, Aura Biosciences, Avila Therapeutics, Cn Creative, EUSA Pharma.
- What companies has Raj Parekh invested in?
- Investments tracked here include Amphista Therapeutics, Avila Therapeutics, Biocartis Group NV, F2G, Levicept, Nerre Therapeutics, Rappta Therapeutics, Thiakis, Zikani Therapeutics.
About this profile. Compiled from public sources — Advent Life Sciences's own website, regulatory filings and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights